Katherine MacLean
Research Psychologist and Psychedelic Researcher
Data updated
Research Footprint
Katherine MacLean appears in 9 tracked papers (2011–2021), most studied alongside Psilocybin, Salvia Divinorum and MDMA, across Healthy Volunteers, Depressive Disorders and Major Depressive Disorder (MDD).
Most-cited paper: Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness (904 citations).
Frequent co-authors: Roland Griffiths, Matthew Johnson and Thomas Prisinzano.
Background & Research
Katherine A. MacLean, PhD, is a research psychologist whose work centres on human psychopharmacology, clinical applications of classic and atypical psychedelics, and the psychometric and ethical questions that arise in psychedelic-assisted therapies. Her research portfolio spans controlled laboratory dose–response studies of compounds such as salvinorin A (a kappa-opioid agonist) through to clinical and secondary-analytical work on psilocybin-assisted therapy and its effects on personality and subjective mystical-type experiences. MacLean combines quantitative experimental designs with psychometric evaluation and qualitative inquiry to probe both acute drug effects and longer-term psychological change.
Key Impact
Notable for experimental human psychopharmacology of novel hallucinogens and influential work on psilocybin's effects on personality and the measurement of mystical-type experiences.
Collaboration Network
13 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Katherine MacLean is associated with.